Clinical Study of PIC1 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07456371 Phase 1 RECRUITING

This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.

Details

Lead sponsor	Chongqing Precision Biotech Co., Ltd
Phase	Phase 1
Status	RECRUITING
Enrolment	18
Start date	2026-03
Completion	2029-02

Conditions

• Non-Hodgkin Lymphoma

Interventions

• PIC1 Injection

Primary outcomes

• Incidence of Adverse Events (AEs) after infusion — 1 month
  Types, frequency and severity of adverse events.

Countries

China